Monthly Oncology Tumor Board Series

NCCN is offering a series of twelve multidisciplinary case-based webinars on a variety of topics, including Follicular Lymphoma, CLL, CML, multiple myeloma, triple negative breast cancer, hormone sensitive breast cancer, squamous cell carcinoma of the lung, advanced adenocarcinoma of the lung, colorectal cancer, prostate cancer, melanoma, and kidney cancer. Each webinar will be facilitated by two faculty members providing multidisciplinary perspectives. A different topic will be presented each month for twelve months (May 2013 until April 2014).

The NCCN Guidelines are a set of step-by step evidence-based, consensus-driven recommendations that ensure that patients receive preventive, diagnostic, treatment, and care that is most likely to lead to optimal outcomes. The NCCN recommendations are applicable to about 95% of patients. Clinicians need to consider the current clinical status of the patient, including general health, disease specifics, concomitant conditions, current and previous therapies, and the patients how to best apply appropriate standard of care including identifying circumstances where appropriate management requires adapting the NCCN Guidelines to the needs of the individual. This activity series will discuss the specific recommendations in the NCCN Guidelines as well as unique patient circumstances that impact how the NCCN Guidelines might be best applied.

Intended Audience
These educational programs are designed to meet the educational needs of oncologists, pathologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

These activities are approved for AMA PRA Category 1 Credit(s)™. Nursing and pharmacy (ACPE) credits are also provided for all sessions. Complete accreditation information is provided before each individual educational activity.

Fee Information
There are no fees for these activities.

These activities are supported by educational grants from Daiichi Sankyo, Inc.; Genentech; Millennium: The Takeda Oncology Company; Novartis Pharmaceuticals Corporation; and Teva Pharmaceuticals. These activities are supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. These activities are supported by a grant from Onyx Pharmaceuticals.


Upcoming Live Webinars

Click on a title below to register.

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Prostate Cancer
Tuesday, April 22, 2014 • 12:30 - 1:30 PM EST
Philip W. Kantoff, MD, and Paul Nguyen, MD
Dana-Farber/Brigham and Women’s Cancer Center



Recorded Webcasts

Each live webinar will be archived and available for viewing approximately 2 weeks after the live webinar ends.
Click on a title below to proceed.

Please log in or register to take this Activity set.